Current Headlines

  1. Kymab And LifeArc Enter Strategic Partnership To Discover New Medicines Using Kymab’s IntelliSelect® Technologies

    Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced a strategic partnership agreement with LifeArc, a leading UK medical research charity

  2. Athenex Announces U.S. FDA Allowance Of Investigational New Drug Application For PT01 (Pegtomarginase)

    Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has allowed the Company’s Investigational New Drug (IND) application for the clinical investigation of PT01 (Pegtomarginase) for the treatment of patients with advanced malignancies

  3. Scientists Uncover New Method For Developing Tracers Used For Medical Imaging

    In an advance for medical imaging, scientists from University of North Carolina Lineberger Comprehensive Cancer Center have discovered a method for creating radioactive tracers to better track pharmaceuticals in the body as well as image diseases, such as cancer, and other medical conditions

  4. Human-On-A-Chip Model Enables Simultaneous Testing Of Cancer Drug Efficacy And Off-Target Toxicity To Enable Determination Of Therapeutic Index

    A reconfigurable “body-on-a-chip” model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organs, such as the heart and liver

  5. Ricoh Announces Strategic Business Partnership With Elixirgen Scientific

    Ricoh Company, Ltd., (Tokyo, Japan) today announced it has entered into a strategic business partnership with Elixirgen Scientific, Inc., (Baltimore, Maryland, USA), to develop innovative biomedical products and services that support drug discovery based on cell differentiation*1 technology

  6. Gilead And Nurix Establish Strategic Collaboration To Develop Novel Therapies For Cancer And Other Diseases

    Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases

  7. Denovo Biopharma Receives Global Rights To A Novel Late-Stage Drug For Alzheimer's Disease From Orion Corporation For Development As A Personalized Medicine

    Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has licensed ORM-12741 from Orion Corporation. Denovo gains global rights to develop, manufacture and commercialize ORM-12741

  8. New Drug Compound Could Tackle Major Life-Limiting Kidney Disease

    Scientists from the University of Sheffield are part of an international collaboration to develop a new class of drugs to treat a common genetic kidney disease which is a major cause of kidney failure

  9. Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio By Acquiring NexusPharma

    Genesis Drug Discovery & Development (GD3), the contract research organization (CRO) of Genesis Biotechnology Group® (GBG), announced that it has expanded its drug development services through the acquisition of a majority interest in NexusPharma

  10. Personalized Stem Cells, Inc. Submits Investigational New Drug (IND) Application For The Treatment Of Osteoarthritis With Stem Cells

    Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, has submitted an Investigational New Drug (IND) application to the FDA for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical trial uses stem cells as a treatment of osteoarthritis in the knee